HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

S Gail Eckhardt Selected Research

Epidermal Growth Factor (EGF)

4/2016Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
8/2013Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


S Gail Eckhardt Research Topics

Disease

124Neoplasms (Cancer)
12/2023 - 01/2002
31Colorectal Neoplasms (Colorectal Cancer)
03/2024 - 07/2006
12Melanoma (Melanoma, Malignant)
12/2023 - 07/2002
10Triple Negative Breast Neoplasms
10/2022 - 01/2013
6Neutropenia
04/2016 - 11/2004
6Colonic Neoplasms (Colon Cancer)
01/2013 - 07/2006
5Pancreatic Neoplasms (Pancreatic Cancer)
04/2016 - 09/2006
5Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2016 - 11/2004
5Breast Neoplasms (Breast Cancer)
05/2014 - 05/2006
5Thrombocytopenia (Thrombopenia)
09/2009 - 09/2006
4Ovarian Neoplasms (Ovarian Cancer)
12/2023 - 02/2011
4Adenocarcinoma
01/2021 - 09/2006
4Diarrhea
08/2013 - 07/2002
4Nausea
08/2013 - 07/2002
4Lung Neoplasms (Lung Cancer)
10/2010 - 02/2002
3Hematologic Neoplasms (Hematological Malignancy)
01/2023 - 05/2012
3Fatigue
01/2022 - 07/2002
3Adenocarcinoma of Lung
01/2019 - 08/2006
3Exanthema (Rash)
01/2018 - 11/2007
3Disease Progression
05/2013 - 10/2004
3Fever (Fevers)
09/2009 - 07/2002
3Carcinoma (Carcinomatosis)
09/2009 - 08/2005
2Hepatocellular Carcinoma (Hepatoma)
01/2022 - 09/2009
2Pain (Aches)
01/2022 - 02/2009
2Biliary Tract Neoplasms (Biliary Tract Cancer)
01/2021 - 08/2005
2Gastrointestinal Neoplasms (Gastrointestinal Cancer)
02/2020 - 09/2009
2Neoplasm Metastasis (Metastasis)
01/2018 - 01/2016
2Renal Cell Carcinoma (Grawitz Tumor)
01/2017 - 03/2007

Drug/Important Bio-Agent (IBA)

16Biomarkers (Surrogate Marker)IBA
01/2023 - 06/2006
15Phosphotransferases (Kinase)IBA
12/2018 - 07/2006
12Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
12/2023 - 11/2006
9Irinotecan (Camptosar)FDA LinkGeneric
01/2021 - 08/2007
8Proteins (Proteins, Gene)FDA Link
11/2021 - 09/2008
7Tyrosine Kinase InhibitorsIBA
01/2022 - 11/2007
7LigandsIBA
01/2022 - 07/2008
7AZD 6244IBA
01/2018 - 05/2008
7Monoclonal AntibodiesIBA
01/2018 - 08/2006
7ErbB Receptors (EGF Receptor)IBA
10/2010 - 08/2006
6Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
11/2020 - 08/2006
6Docetaxel (Taxotere)FDA Link
03/2010 - 08/2003
5PlatinumIBA
12/2023 - 02/2002
5Histone Deacetylase InhibitorsIBA
12/2023 - 07/2008
5Immune Checkpoint InhibitorsIBA
01/2022 - 01/2020
5Capecitabine (Xeloda)FDA Link
01/2021 - 08/2007
5GemcitabineFDA Link
04/2016 - 10/2003
4Carboplatin (JM8)FDA LinkGeneric
01/2021 - 10/2005
4Paclitaxel (Taxol)FDA LinkGeneric
01/2021 - 10/2005
4Aurora Kinase AIBA
01/2020 - 06/2010
43- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA
12/2018 - 11/2010
4EnzymesIBA
01/2018 - 07/2002
4ENMD 2076IBA
01/2017 - 06/2010
4vandetanib (ZD6474)IBA
04/2016 - 07/2006
4Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
04/2016 - 11/2007
4Glucose (Dextrose)FDA LinkGeneric
01/2016 - 10/2004
4Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2016 - 09/2008
4Imatinib Mesylate (Gleevec)FDA Link
02/2013 - 10/2004
4Cetuximab (Erbitux)FDA Link
10/2010 - 08/2006
4Tyrosine (L-Tyrosine)FDA Link
06/2010 - 07/2006
3CateninsIBA
11/2020 - 03/2014
3AntigensIBA
10/2020 - 01/2017
3MLN 8237IBA
01/2020 - 05/2015
3Oxaliplatin (Eloxatin)FDA LinkGeneric
01/2018 - 07/2006
3CreatinineIBA
01/2018 - 08/2002
3Enzyme Inhibitors (Inhibitors, Enzyme)IBA
01/2017 - 12/2008
3IGF Type 1 Receptor (IGF 1 Receptor)IBA
11/2010 - 04/2010
3Bortezomib (Velcade)FDA Link
10/2010 - 02/2009
3Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
06/2010 - 08/2006
3phosphomannopentaose sulfateIBA
03/2010 - 09/2006
3Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA
02/2010 - 10/2005
3Gefitinib (Iressa)FDA Link
04/2009 - 11/2007
2RNA (Ribonucleic Acid)IBA
03/2024 - 01/2019
2Histone Deacetylases (Histone Deacetylase)IBA
12/2023 - 01/2022
2cabozantinibIBA
01/2022 - 10/2018
2Granzymes (Granzyme)IBA
01/2022 - 01/2020
2adavosertibIBA
01/2021 - 03/2020
2RX-5902IBA
11/2020 - 11/2019
2Bevacizumab (Avastin)FDA Link
11/2020 - 05/2006
2DNA (Deoxyribonucleic Acid)IBA
10/2019 - 05/2006
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2019 - 05/2013
2c-Mer Tyrosine KinaseIBA
01/2019 - 05/2013
2Insulin ReceptorIBA
12/2018 - 11/2013
2Immunoglobulin G (IgG)IBA
01/2018 - 02/2010
2Cyclosporine (Ciclosporin)FDA LinkGeneric
01/2018 - 08/2013
2Sorafenib (BAY 43-9006)FDA Link
01/2017 - 10/2010
2Mitogen-Activated Protein KinasesIBA
01/2017 - 10/2010
2Protein Kinases (Protein Kinase)IBA
01/2017 - 05/2014
2Epidermal Growth Factor (EGF)IBA
04/2016 - 08/2013
2TAK 733IBA
10/2015 - 02/2015
2Phosphatidylinositols (Phosphatidylinositol)IBA
03/2014 - 05/2012
2Polo-Like Kinase 1IBA
03/2014 - 04/2012
2ON 01910IBA
03/2014 - 04/2012
2Small Interfering RNA (siRNA)IBA
08/2013 - 05/2013
2AgarIBA
05/2013 - 10/2010
2PF 3758309IBA
01/2013 - 01/2013

Therapy/Procedure

38Therapeutics
01/2022 - 02/2002
12Drug Therapy (Chemotherapy)
01/2022 - 01/2002
8Immunotherapy
01/2023 - 01/2016
3Radiotherapy
10/2010 - 10/2008
2Aftercare (After-Treatment)
01/2017 - 07/2003
2Drug Tapering
08/2013 - 08/2002